# BeiGene

aggressively developing and commercializing original oncology biologics for both domestic and international markets.

Source: https://en.bioecon.ru/companies/beigene/
Updated: 2026-06-24

- Country: China
- Ticker: BGNE

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2010 (2010) | https://www.businesswire.com/news/home/20210407005897/en/BeiGene-Announces-First-Commercial-Manufacturing-Approval-for-Its-State-of-the-Art-Biologics-Facility-in-Guangzhou-China, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/R9.htm |
| Headcount | 11,000+ employees worldwide (2024-12-31) | https://ir.beonemedicines.com/news/beigene-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-updates/ae4b526f-e135-4ce7-84fe-e9a8ba557406, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/R9.htm |
| Revenue | $3.81 billion USD for full year 2024 (2024-12-31) | https://ir-api.eqs.com/media/document/6d80cd79-1b6f-4b3f-a71e-f4c6b04211ff/assets/BGNE-Earnings_Presentation_Q4_FY_2024_final.pdf?disposition=inline, https://last10k.com/sec-filings/onc/0001651308-25-000031.htm |
| Production site | Guangzhou, China (39-acre site); Suzhou, China (12.4-acre site); Hopewell, New Jersey, US (42-acre site) (2024-11-01) | https://beonemedicines.com/about/manufacturing/, https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| Capacity | Guangzhou: 65,000L biologics (expandable to 200,000L), 600M OSD; Suzhou: 300M tablet & 300M capsule, 1kL biologics; Hopewell: 8,000L biologics (expandable to 16,000L) (2024-11-01) | https://beonemedicines.com/about/manufacturing/, https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| Certification | GMP standards (US FDA, EMA, TGA, China NMPA, ANVISA, etc.) (2024-11-01) | https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf |
| Regulatory approval | 30+ approvals and inspections including US FDA, EMA, and China NMPA; medicines approved in 70+ markets (2024-12-31) | https://beonemedicines.com/wp-content/uploads/2025/01/BeiGene-Global-Manufacturing-Facilities-Overview_Nov2024.pdf, https://ir.beonemedicines.com/news/beigene-announces-fourth-quarter-and-full-year-2024-financial-results-and-business-updates/ae4b526f-e135-4ce7-84fe-e9a8ba557406, https://www.businesswire.com/news/home/20210407005897/en/BeiGene-Announces-First-Commercial-Manufacturing-Approval-for-Its-State-of-the-Art-Biologics-Facility-in-Guangzhou-China |

Independent sources: beonemedicines.com, businesswire.com, ir-api.eqs.com, ir.beonemedicines.com, last10k.com, sec.gov

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [Bispecific & multispecific antibodies](https://en.bioecon.ru/technology/bispecific-antibodies/)
- [PROTACs (targeted protein degradation)](https://en.bioecon.ru/technology/protacs/)